Table 2.
Prevalence of Medication Use or Lifestyle Counseling in Patients with Peripheral Artery Disease Seeing Physicians in U.S. Ambulatory Care Visits, 2006–2013
| All PAD, Years 2006–2013 | ||||
|---|---|---|---|---|
|
| ||||
| Characteristic | Unweighted Visits, n | Annual Weighted Visits, n | Percent, % | Std. Err. |
| Medical Therapy | ||||
| Any antiplatelet therapy | 633 | 1,400,619 | 37.8 | 2.6 |
| Aspirin | 497 | 1,059,044 | 28.6 | 2.2 |
| Clopidogrel | 287 | 699,383 | 18.1 | 1.9 |
| Statin | 557 | 1,297,320 | 35.0 | 2.4 |
| ACE-I/ARB | 482 | 1,152,083 | 31.1 | 2.0 |
| Cilostazol | 71 | 186,216 | 5.0 | 1.0 |
| Lifestyle Counseling | ||||
| Exercise or diet counseling | 299 | 745,081 | 20.1 | 2.2 |
| Smoking Cessation | 146 | 274,752 | 36.3 | 3.9 |
Abbreviations: ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker
Note: All analyses account for the complex sampling design of the NAMCS and NHAMCS